Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis
IntroductionNon-small cell lung cancer (NSCLC) constitutes approximately 80–85% of cancer-related fatalities globally, and direct and indirect comparisons of various therapies for NSCLC are lacking. In this study, we aimed to compare the efficacy and safety of immune checkpoint inhibitors (ICIs) in...
Saved in:
| Main Authors: | Lin Zhu, Wenjuan He, Cunlei Xie, Yang Shu, Chunxia Zhang, Yawen Zhu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1512468/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of immunotherapy for head and neck squamous cell carcinoma: a meta-analysis of randomized clinical trials
by: Cailing Jiang, et al.
Published: (2025-01-01) -
Prognosis of Tyrosine Kinase Inhibitor Therapy for Non-Small Cell Lung Cancer
by: Agus Andreas Santoso, et al.
Published: (2025-05-01) -
Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
by: Mandy Jongbloed, MD, et al.
Published: (2025-03-01) -
Thrombotic events in patients with multiple myeloma and their impact on overall survival
by: Haimin Chen, et al.
Published: (2025-12-01) -
The prognostic value of circulating tumor DNA in malignant melanoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
by: Lei Liu, et al.
Published: (2025-01-01)